EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry
(2010) In European Journal of Nuclear Medicine and Molecular Imaging 37(6). p.1238-1250- Abstract
- The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. The guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of... (More)
- The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. The guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the cross-absorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body. As radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single- and multi-centre radionuclide therapy studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1617903
- author
- Hindorf, Cecilia ; Glatting, Gerhard ; Chiesa, Carlo ; Lindén, Ola LU and Flux, Glenn
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Internal dosimetry, Radionuclide therapy, Bone marrow
- in
- European Journal of Nuclear Medicine and Molecular Imaging
- volume
- 37
- issue
- 6
- pages
- 1238 - 1250
- publisher
- Springer
- external identifiers
-
- wos:000277639400025
- scopus:77954886801
- pmid:20411259
- ISSN
- 1619-7070
- DOI
- 10.1007/s00259-010-1422-4
- language
- English
- LU publication?
- yes
- id
- 999097eb-429c-4cc6-91dc-50dbab0f740d (old id 1617903)
- alternative location
- http://www.ncbi.nlm.nih.gov/sites/pubmed
- date added to LUP
- 2016-04-01 10:08:42
- date last changed
- 2022-04-27 18:53:20
@article{999097eb-429c-4cc6-91dc-50dbab0f740d,
abstract = {{The level of administered activity in radionuclide therapy is often limited by haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The purpose of these EANM guidelines is to provide advice to scientists and clinicians on data acquisition and data analysis related to bone-marrow and whole-body dosimetry. The guidelines are divided into sections "Data acquisition" and "Data analysis". The Data acquisition section provides advice on the measurements required for accurate dosimetry including blood samples, quantitative imaging and/or whole-body measurements with a single probe. Issues specific to given radiopharmaceuticals are considered. The Data analysis section provides advice on the calculation of absorbed doses to the whole body and the bone marrow. The total absorbed dose to the bone marrow consists of contributions from activity in the bone marrow itself (self-absorbed dose) and the cross-absorbed dose to the bone marrow from activity in bone, larger organs and the remainder of the body. As radionuclide therapy enters an era where patient-specific dosimetry is used to guide treatments, accurate bone-marrow and whole-body dosimetry will become an essential element of treatment planning. We hope that these guidelines will provide a basis for the optimization and standardization of the treatment of cancer with radiopharmaceuticals, which will facilitate single- and multi-centre radionuclide therapy studies.}},
author = {{Hindorf, Cecilia and Glatting, Gerhard and Chiesa, Carlo and Lindén, Ola and Flux, Glenn}},
issn = {{1619-7070}},
keywords = {{Internal dosimetry; Radionuclide therapy; Bone marrow}},
language = {{eng}},
number = {{6}},
pages = {{1238--1250}},
publisher = {{Springer}},
series = {{European Journal of Nuclear Medicine and Molecular Imaging}},
title = {{EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry}},
url = {{http://dx.doi.org/10.1007/s00259-010-1422-4}},
doi = {{10.1007/s00259-010-1422-4}},
volume = {{37}},
year = {{2010}},
}